Management Team


Leah Makley


Leah received a Ph.D. in medicinal chemistry from the University of Michigan in 2014, and a B.S. in biochemistry from the University of Dayton in 2009. She developed ViewPoint's flagship technology as a graduate student in Jason's lab and cofounded the company. While at the University of Michigan, she participated in the Pharmacological Sciences Training Program, was a fellow of the American Foundation for Pharmaceutical Education, and was named an Alzheimer's Drug Discovery Foundation Young Investigator. Leah has expertise in biophysical methods, protein biochemistry, high-throughput screening, and medicinal chemistry. 




Bob joined Viewpoint Therapeutics as Chief Medical Officer in May 2018. He is a board-certified ophthalmologist who comes to Viewpoint from Genentech, Novartis, GSK, Carl Zeiss Meditec, and most recently Apellis Pharmaceuticals. He has been involved in Phase 1-3 development of numerous drugs, including Lucentis, Simbrinza, Pazeo, and most recently pegcetacoplan (APL-2). Bob completed his residency in ophthalmology at the University of California, San Francisco (UCSF), post-doctoral training in molecular biology of lens crystallins at the NIH, and retina fellowship training at Moorfields Eye Hospital in London. He received his undergraduate and MD degrees from Brown University and an MBA from UC Berkeley. He is currently an Associate Clinical Professor of Ophthalmology at UCSF, where he continues to see patients.



Brian Connolly


Brian joined ViewPoint in October 2018 as Senior Director of Project Management.   He has over 13 years of experience in drug development, clinical/commercial manufacturing, team leadership, and project & portfolio management.  Most recently, Brian contributed to the NDA approval and commercial launch of ZEMDRI (plazomicin) at Achaogen with responsibilities in team leadership, project management, and commercial manufacturing operations.  Prior to Achaogen, Brian was at Genentech for over 12 years where he was responsible for the global Roche/Genentech CMC portfolio budget planning process and contributed to the development and commercialization of Avastin (bevacizumab), Ocrevus (ocrelizumab) Subcutaneous Delivery, Ranibizumab Sustained Delivery, Ranibizumab Port Delivery System, Mosunetuzumab, BFCR4350A, and other early development small molecule and large molecule NMEs in various roles of increasing leadership over the years.  Brian holds a B.S. in Bioengineering from the University of California, San Diego.


ViewPoint is further supported by a team of consultants and contractors with deep expertise in medicinal chemistry, formulations, preclinical and clinical development, chemistry manufacturing, and regulatory affairs.